

LETTERS TO THE EDITOR

in malignant mesothelioma did not refer to a study of Vogelzang et al² about pemetrexed (Alimta[®]) with cisplatin versus cisplatin alone. In that study a survival advantage of approximately 3 months was found for the combination. Recent reviews from experts on mesothelioma now consider this combination to be standard therapy,³⁻⁵ although discussion continues.⁶ Also, a paper in *The Lancet* exploring mesothelin as an early serum marker for upcoming mesothelioma or for follow-up⁷ seems an interesting future option to consider in the diagnosis of mesothelioma.

I hope you will appreciate these additions.

E. J. Van Hezik
MD, Pulmonologist

Chest Department, Walcheren Hospital,
POB 3200, 4380 DD Vlissingen,
The Netherlands.

Malignant Pleural Mesothelioma: Further Options

To the editor: Reading the guidelines on asbestos-related pleuropulmonary disease,¹ I noted that the chapter on treatment options

1. Isidro Montes I, Abu-Shams K, Alday E, Carretero Sastre JL, Ferrer Sancho J, Freixa Blanxart A, et al. Normativa sobre el asbesto y sus enfermedades pleuropulmonares. *Arch Bronconeumol.* 2005;41:153-68.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol.* 2003;21:2636-44.
3. Nowak AK, Byrne MJ, Millward MJ, Álvarez JM, Robinson BW. Current chemotherapeutic treatment of malignant pleural mesothelioma. *Expert Opin Pharmacother.* 2004;5:2441-9.
4. Bunn P Jr. New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed. *Oncology.* 2004; 18 Suppl 5:5-11.
5. Rusch V. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? *J Clin Oncol.* 2003;21:2636.
6. Aelony Y. Need for further information on pemetrexed study. *J Clin Oncol.* 2004;22:4234-5.
7. Robinson BWS, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. *Lancet.* 2003;362:1612-6.